The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis.
10.5534/wjmh.2014.32.1.28
- Author:
Sung Won LEE
1
;
Jae Seung PAICK
;
Hyun Jun PARK
;
Ji Eon WON
;
Yoji MORISAKI
;
Sebastian SORSABURU
;
Lars VIKTRUP
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Benign prostatic hyperplasia;
Korean;
Lower urinary tract symptoms;
Phosphodiesterase type 5 inhibitors;
Tadalafil
- MeSH:
Asian Continental Ancestry Group;
Humans;
Lower Urinary Tract Symptoms*;
Male;
Phosphodiesterase 5 Inhibitors;
Prostate;
Prostatic Hyperplasia*;
Quality of Life;
Residual Volume;
Tadalafil
- From:The World Journal of Men's Health
2014;32(1):28-35
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This post hoc integrated analysis assessed the efficacy and safety of tadalafil 5 mg once daily in a large Korean population with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS). MATERIALS AND METHODS: Individual Korean participant data were integrated from three 12-week, randomized, double-blind, placebo-controlled studies in Asian men with BPH-LUTS, wherein 177 Korean men received placebo and 177 received tadalafil 5 mg once daily. The primary objective was to compare the change from baseline to week 12 in total International Prostate Symptom Score (IPSS) after treatment with tadalafil versus placebo. RESULTS: A significantly greater improvement (p<0.001) in total IPSS from baseline to week 12 was observed for tadalafil compared to placebo (least squares mean: tadalafil=-5.97; placebo=-3.94 ). Total IPSS at weeks 4 and 12, IPSS voiding and storage subscores at weeks 4, 8, and 12, and IPSS quality of life index at weeks 8 and 12 were also significantly improved (p<0.05) for tadalafil compared to placebo. There was significant improvement (p<0.001) in the patient global Impression of improvement responses and numerical improvement in the clinician global impression of improvement responses with tadalafil compared to placebo. There were no significant treatment differences for peak urine flow rate or postvoid residual volume . Few participants had treatment-emergent adverse events and there were no unexpected safety findings. CONCLUSIONS: This integrated analysis of three randomized, placebo-controlled Asian studies confirmed tadalafil 5 mg once daily as an efficacious and well-tolerated treatment for Korean men with BPH-LUTS.
